Format

Send to

Choose Destination
Cytotherapy. 2009;11(6):698-705. doi: 10.3109/14653240903051558.

Mesenchymal stem cells are functionally abnormal in patients with immune thrombocytopenic purpura.

Author information

1
Servicio de Hematología, Hospital Clínico Universitario y Centro de Investigación del Cáncer de Salamanca, Spain. pesimop@usal.es

Abstract

BACKGROUND AIMS:

Immune thrombocytopenic purpura (ITP) is a bleeding disorder characterized by an accelerated destruction of platelets as a result of the presence of autoreactive antibodies. Patients with ITP also display activated platelet-autoreactive T cells. Mesenchymal stem cells (MSC) inhibit both T- and B-cell activation and may have functional impairments in autoimmune disorders.

METHODS:

We analyzed the potential role of MSC in the pathogenesis of ITP.

RESULTS:

MSC from ITP showed an impaired proliferative capacity and a lower capability of inhibiting activated T-cell proliferation compared with healthy donors. While MSC from controls showed a decreased expression of p27 after stimulation with platelet-derived growth factor, this effect was not observed in MSC from patients. Furthermore, MSC from healthy donors down-regulated p16 upon exposure to platelet-released supernatant, while this effect was not observed for ITP. Interestingly, caspase 9 expression was higher in MSC from ITP.

CONCLUSIONS:

These abnormalities suggest a role of MSC malfunction in the physiopathology of the disease and may have therapeutic implications.

PMID:
19878056
DOI:
10.3109/14653240903051558
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center